Preliminary results from the GO39775 study show promising efficacy and manageable toxicity for BFCR4350A as monotherapy in patients with RRMM with high-risk cytogenetics, triple-class refractory disease, and/or prior exposure to anti-CD38 monoclonal antibodies, CAR T-cells, or antibody–drug conjugates.

Preliminary results from this phase 1b/2 study of cobimetinib alone or plus venetoclax, with or without atezolizumab, in patients with RRMM show manageable toxicity, moderate efficacy overall, and higher efficacy for t(11;14) patients.

Interim results from a phase 2 trial exploring the response to ixazomib, lenalidomide, and dexamethasone induction followed by a single autologous stem-cell transplantation, IRd consolidation, and risk-based maintenance showed an overall response rate of 93%.

The ICARIA-MM investigators studied the effects of isatuximab + pomalidomide and dexamethasone in the subgroup of frail patients with RRMM, and results support use of the regimen among these patients.

In the FORTE trial, patients with NDMM who were transplant-eligible experienced significantly improved progression-free survival with carfilzomib + lenalidomide + dexamethasone (KRd) induction-ASCT-KRd consolidation versus either 12 KRd cycles or carfilzomib + cyclophosphamide + dexamethasone (KCd) induction-ASCT-KCd consolidation.

Preliminary results from the phase 1b/2 CARTITUDE-1 study reveal early, deep, and durable responses and a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM.

Updated analysis of the phase 1 CRB-401 study supports a favorable clinical benefit–risk profile for the BCMA-directed CAR T-cell therapy, idecabtagene vicleucel, in RRMM at target dose levels of ≥150 × 106 CAR+ T-cells.

For patients with recurrent ovarian cancer progressing within 6 to 12 months after their last platinum line, a combination of trabectedin and pegylated liposomal doxorubicin (PLD) did not demonstrate superiority over a combination of carboplatin and PLD.

XMT-1536 is an antibody-drug conjugate that targets the sodium-phosphate cotransporter NaPi2b, which is commonly expressed in solid tumors such as high-grade serous ovarian cancer. Treatment with XMT-1536 results in an overall response rate of 34% in patients with advanced disease; antitumor activity is positively correlated with a higher NaPi2b expression.

Results from the PAOLA/ENGOT-ov25 study indicate that adding olaparib to maintenance bevacizumab after first-line platinum-based chemotherapy for patients with newly diagnosed high-grade ovarian cancer improves second progression-free survival and time to second subsequent therapy or death.